Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | MDS news from ASH 2018

Alan List • 15 Jan 2019
ASH 2018
Myelodysplastic Syndromes Imetelstat

In this video, Alan List, MD, of Moffitt Cancer Center, Tampa, FL, delivers highlights on myelodysplastic syndrome (MDS) therapies from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. Dr List discusses clinical trials, novel treatments, and progressions which are pushing our understanding of the disease, bringing light to new pathways that can be targeted.

More from Alan List

Inflammation, immune dysregulation and targeting in MDS
Alan List et al. • 24 Jul 2022
1:14
Horizon scan of MDS treatments
Alan List • 5 Mar 2020
0:54
HMAs are the standard, what are their limitations?
Alan List • 5 Mar 2020
1:02
The stages and treatments for myelodysplastic syndromes
Alan List • 5 Mar 2020

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals